ArticleBiophotonics discovery2025
Multimodal esophageal cancer imaging: establishing data processing techniques and assessing diagnostic sensitivity.
Article in Biophotonics discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multimodal optical imaging techniques have generated significant interest for applications such as cancer detection, as combining complementary modalities could broaden the ability to detect early disease changes, as well as address patient-to-patient variability. However, there are challenges in determining how different imaging modalities may or may not complement one another and how best to capitalize on these advantages through computational analysis. We investigate the application of multimodal imaging for the purpose of detecting esophageal cancer, the sixth most deadly cancer in the world. To achieve this, we acquired multimodal optical imaging data-specifically autofluorescence, hyperspectral, polarized light, and optical coherence tomography (OCT)-from fresh human tissue samples obtained during upper endoscopy. Our analysis then addressed three key questions: Which individual modality best differentiates between healthy and cancerous tissues? How can data from these modalities be integrated to maximize discrimination? What computational methods are suitable for analyzing the resulting high-dimensional multimodal datasets? Our findings indicate that polarized light imaging (PLI) exhibits the strongest discriminatory power under these imaging conditions, with potential benefits observed from combining PLI and OCT in a multimodal approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.